2012
DOI: 10.1016/j.bmcl.2011.11.087
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and SAR of inhibitors of protein kinase CK2: Novel tricyclic quinoline analogs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
11
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(12 citation statements)
references
References 28 publications
0
11
0
Order By: Relevance
“…To further restrict our disruption to nucleolar integrity maintained by Pol I activity, we employed a second inhibitor, CX-5461, the first selective inhibitor of Pol I known to directly target the Pol I multienzyme complex [35][37]. Like Act-D, CX-5461 has also been shown to cause rapid nucleolar disruption in cell lines [38].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…To further restrict our disruption to nucleolar integrity maintained by Pol I activity, we employed a second inhibitor, CX-5461, the first selective inhibitor of Pol I known to directly target the Pol I multienzyme complex [35][37]. Like Act-D, CX-5461 has also been shown to cause rapid nucleolar disruption in cell lines [38].…”
Section: Resultsmentioning
confidence: 99%
“…To assess the role of nucleoli in plasticity we disrupted nucleolar function in three ways: 1) 3-AB treatment which blocked regulated plasticity-dependent gene expression; 2) low-dose Act-D treatment which preferentially blocks transcriptional activity at GC–rich rDNA promoters; and 3) application of the highly specific Pol I inhibitor, CX-5461, which directly targets the Pol I multi-enzyme complex [35], [37], [38]. Each drug treatment was expected to directly and/or indirectly target ribosomal biogenesis through its rate limiting step, the production and maturation of rRNA.…”
Section: Discussionmentioning
confidence: 99%
“…For the CX-4945 analogs, two crucial polar interactions exist simultaneously between the pyridine group and the carboxylate substituent with the hinge and positive regions, respectively. Haddach et al (34) synthesized a series of tricyclic quinoline analogs by changing the carboxylate group to a non-ionizable substituent and the carboxylate group at different positions, to investigate the function of the carboxylic acid at the R2 position on inhibitory activity. We built the three-dimensional quantitative structure-activity relationship (3D-QSAR) models for these types of compounds (35).…”
mentioning
confidence: 99%
“…Our results suggest that MAF1 is a key transcription factor controlling tRNA transcription during DC activation. The involvement of CK2 in this process was tested using CX-4945, a specific inhibitor currently used in clinical trials (27,28). Immunoblotting for different targets of CK2 (AKT and eIF2β) was performed to confirm CX-4945's specificity in DCs (Fig.…”
Section: Resultsmentioning
confidence: 99%